SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-25-003615 to AIBOTICS, INC. (AIBT)

AIBOTICS, INC.
Date: April 3, 2025 · CIK: 0001763329 · Accession: 0000000000-25-003615

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 024-12597

Date
April 3, 2025
Author
Division of
Form
UPLOAD
Company
AIBOTICS, INC.

Letter

Re: Aibotics, Inc. Offering Statement on Form 1-A Filed April 2, 2025 File No. 024-12597 Dear Ben Kaplan:

April 3, 2025

Ben Kaplan Chief Executive Officer Aibotics, Inc. 100 SE 2nd St Suite 2000 Miami, FL 33131

Our initial review of your offering statement indicates that it fails in material respects to comply with the requirements of Regulation A and Form 1-A. More specifically, we note that your filing does not include audited financials for the fiscal year ended December 31, 2024.

We will provide more detailed comments relating to your offering statement following our review of a substantive amendment that addresses this deficiency.

Please contact Joe McCann at 202-551-6262 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Jonathan D. Leinwand, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 April 3, 2025

Ben Kaplan
Chief Executive Officer
Aibotics, Inc.
100 SE 2nd St
Suite 2000
Miami, FL 33131

 Re: Aibotics, Inc.
 Offering Statement on Form 1-A
 Filed April 2, 2025
 File No. 024-12597
Dear Ben Kaplan:

 Our initial review of your offering statement indicates that it fails
in material respects
to comply with the requirements of Regulation A and Form 1-A. More
specifically, we note
that your filing does not include audited financials for the fiscal year ended
December 31,
2024.

 We will provide more detailed comments relating to your offering
statement
following our review of a substantive amendment that addresses this deficiency.

 Please contact Joe McCann at 202-551-6262 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Jonathan D. Leinwand, Esq.
</TEXT>
</DOCUMENT>